Navigation Links
Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share
Date:11/22/2011

160;A number of risks and uncertainties could cause actual results to differ materially from these statements, including, without limitation, the success rate of business development efforts and the timeliness of development activities, and other risk factors described from time to time in the Company's reports filed with the SEC.  In addition, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond the Company's control. Denali Concrete Management, Inc. undertakes no obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.  The securities issued in the above transaction have not been and will not be registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.


'/>"/>
SOURCE Denali Concrete Management Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
2. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
3. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
4. Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
5. U.S. Preventive Medicine Acquires Specialty Disease Management
6. Cellectar Expands Clinical Management Team
7. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
8. New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
9. Lilly Receives NCQA Design Certification for Depression Care Management Program
10. Micromet Announces Changes in Management Team
11. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 According ... "Process Spectroscopy Market (Technology Types - Near infrared (NIR) spectroscopy, ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 ... in 2012 and is expected to grow at a CAGR ... North America was the largest contributor to global ...
(Date:7/22/2014)... MOUNTAIN VIEW, Calif. , July 22, 2014 ... magnetic resonance imaging (MRI) market, Frost & Sullivan ... Award for Product Leadership. Siemens Healthcare,s FREEZEit solution, ... addresses the need for robust and motion-insensitive imaging. ... has boosted the evolution of body MRI imaging ...
(Date:7/22/2014)... , July 22, 2014  Halozyme Therapeutics, Inc. ... has resumed enrollment and dosing of patients in its ... patients with pancreatic cancer under the revised clinical protocol ... an investigational PEGylated form of Halozyme,s proprietary recombinant human ... that accumulate hyaluronan. "Our diligent effort ...
Breaking Medicine Technology:Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 2Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 3Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 4Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 2Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 3Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 4Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3
... 2011 Techne Corporation,s (NASDAQ: TECH ) financial ... 30, 2011 include the following highlights: , ... per diluted share.  Earnings for the quarter grew 21.2% to ... intangible asset amortization, costs recognized upon the sale of inventory ...
... 2, 2011 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ... LEVADEX® orally inhaled migraine drug for the potential acute treatment ... the U.S. Food and Drug Administration (FDA), with a goal ... Fee Act (PDUFA). In accordance with the Company,s collaboration agreement ...
Cached Medicine Technology:Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 2Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 3Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 4Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 5Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 6Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 7Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 8Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 9Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 10Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 11MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX® 2MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX® 3MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX® 4
(Date:7/22/2014)... (Boston)-- Researchers from Boston University School of Medicine ... that participants who received care through BMC,s Violence ... physical, mental, emotional and social needs of violently ... injuries and experienced life changing behaviors through connections ... feel trust and hope. These findings are reported ...
(Date:7/22/2014)... The European Bio stimulants Market report defines ... analysis and forecast of revenue. The bio stimulants market ... million in 2013 to $940.6 million by 2018, at ... Browse through the TOC of the Europe Bio stimulants ... analysis provided. , http://www.micromarketmonitor.com/market/europe-bio-stimulants-1315565884.html , Agriculture contributes ...
(Date:7/22/2014)... California (PRWEB) July 22, 2014 In ... women in recovery, the Marinello School of Beauty joined ... Addiction Treatment Center for a free “Make-over Day.” ... to be of service to the community, and The ... and renewed. They also gained some first-hand experience about ...
(Date:7/22/2014)... 2014 Expert Publishing ... , announces the launch of PoisonEXPERT™ , ... safety professionals employed by organizations that use or ... manage the impact of chemicals on their employees ... relevant chemical-specific information and medical protocols that allows ...
(Date:7/22/2014)... Transparency Market Research has announced the ... Diagnostics Market – Global Industry Analysis, Size, Share, Growth, ... comprehensive database. This industry is considered as the most ... valued at USD 8.7 billion by 2019 and expected ... to 2019. Molecular diagnostics is the class of diagnostic ...
Breaking Medicine News(10 mins):Health News:Clients of BMC's violence interventional advocacy program find experience supportive 2Health News:Clients of BMC's violence interventional advocacy program find experience supportive 3Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:The Discovery House 'Make-over Day' Adds Pampering To Recovery 2Health News:The Discovery House 'Make-over Day' Adds Pampering To Recovery 3Health News:PoisonEXPERT™ from ExPub Now Available 2Health News:PoisonEXPERT™ from ExPub Now Available 3Health News:Global Molecular Diagnostics Market Expected to Reach USD 8.7 Billion through 2019: Transparency Market Research 2Health News:Global Molecular Diagnostics Market Expected to Reach USD 8.7 Billion through 2019: Transparency Market Research 3Health News:Global Molecular Diagnostics Market Expected to Reach USD 8.7 Billion through 2019: Transparency Market Research 4
... a Diet High in Fruits and Vegetables ,Healthy Foods ... patients with kidney disease, the Western diet produces an acidic ... worsens with age as kidney function declines. Nimirit Goraya, MD ... and her colleagues conducted a study to see if consuming ...
... By Ellin Holohan HealthDay Reporter , FRIDAY, ... against alcohol use, can relax and have a drink a ... weight, two new Dutch studies show. The researchers found ... be unfounded, while concerns about weight are not. Both ...
... 19 (HealthDay News) -- A new, small study suggests that the ... dose of tamoxifen, a drug commonly used to prevent and treat ... cough medicine at about the same rate as tamoxifen, allowing doctors ... drug. "This study is starting to identify a personalized ...
... NEW YORK (Nov. 20, 2010) Columbia University Medical ... a Harvard researcher who has made important advances in ... and heart disease. A promising young investigator at Columbia ... the basis for disordered lipid metabolism in diabetes. ...
... By Madonna B